Orajel Cold Sore Moisturelock

Benzocaine


Church & Dwight Co., Inc.
Human Otc Drug
NDC 10237-761
Orajel Cold Sore Moisturelock also known as Benzocaine is a human otc drug labeled by 'Church & Dwight Co., Inc.'. National Drug Code (NDC) number for Orajel Cold Sore Moisturelock is 10237-761. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Orajel Cold Sore Moisturelock drug includes Allantoin - 5 mg/g Benzocaine - 200 mg/g Camphor (natural) - 30 mg/g Dimethicone - 20 mg/g Menthol - 10 mg/g Petrolatum - 640 mg/g . The currest status of Orajel Cold Sore Moisturelock drug is Active.

Drug Information:

Drug NDC: 10237-761
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Orajel Cold Sore Moisturelock
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Benzocaine
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Church & Dwight Co., Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ALLANTOIN - 5 mg/g
BENZOCAINE - 200 mg/g
CAMPHOR (NATURAL) - 30 mg/g
DIMETHICONE - 20 mg/g
MENTHOL - 10 mg/g
PETROLATUM - 640 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jul, 2016
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 05 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part356
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Church & Dwight Co., Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2257305
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0310310998820
UPC stands for Universal Product Code.
NUI:N0000185508
N0000175629
N0000184306
M0000728
N0000010282
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:344S277G0Z
U3RSY48JW5
N20HL7Q941
92RU3N3Y1O
L7T10EIP3A
4T6H12BN9U
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Standardized Chemical Allergen [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Skin Barrier Activity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Increased Histamine Release [PE]
Skin Barrier Activity [PE]
Standardized Chemical Allergen [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
10237-761-011 TUBE in 1 CARTON (10237-761-01) / 3 g in 1 TUBE01 Jul, 2016N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Allantoin - skin protectant benzocaine - topical anesthetic camphor - topical analgesic dimethicone - skin protectant menthol - topical analgesic white petrolatum - skin protectant

Product Elements:

Orajel cold sore moisturelock benzocaine medium-chain triglycerides prunella vulgaris leaf titanium dioxide fd&c yellow no. 5 propylene glycol .alpha.-tocopherol acetate vitamin a palmitate corn oil cholecalciferol ferric oxide red fd&c blue no. 1 tocopherol benzocaine benzocaine allantoin allantoin camphor (natural) camphor (natural) dimethicone dimethicone menthol menthol petrolatum petrolatum

Indications and Usage:

Uses • temporarily relieves pain and dryness; softens crusts (scabs) associated with • cold sores • fever blisters

Warnings:

For external use only. allergy alert: do not use if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine or other "caine" anesthetics

Do Not Use:

For external use only. allergy alert: do not use if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine or other "caine" anesthetics

When Using:

When using this product • do not get into eyes

Dosage and Administration:

Directions • squeeze tube to dispense • blend well until green tint disappears • rub in gently adults and children 2 years of age and older | apply to affected area not more than 3 to 4 times daily children under 12 years of age | should be supervised in the use of this product children under 2 years of age | ask a physician other information • do not use if the package is torn, cut or otherwise damaged • store at 15-30ºc (59-86º) under dry conditions • this is a personal care item and should be used by one individual only

Stop Use:

Stop use and ask a physician if • conditions worsens • symptoms do not improve in 7 days • symptoms clear up and occur again within a few days • swelling, rash or fever develops • irritation, pain or redness persists or worsens

Package Label Principal Display Panel:

Orajel instan pain relief for cold sores moisturelock formula helps speed healing treats 6 symptoms: 1 pain 2 itching 3 redness 4 scabbing 5 cracking 6 dryness plus helps minimize appearance of cold sores topical anesthetic/topical analgesic/skin protectant net wt 0.105 oz (3g) ft_ojbc-99882-04 bk_ojbc-99882-04

Further Questions:

Questions or comments call us at 800 952 5080 monday through friday 9 to 5 et or visit www orajel com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.